Kardiologie up2date, Table of Contents Kardiologie up2date 2019; 15(01): 75-84DOI: 10.1055/a-0802-1104 Entzündliche Herzerkrankungen und Kardiomyopathien Georg Thieme Verlag KG Stuttgart · New York Peripartum-Kardiomyopathie Tobias König , Constantin von Kaisenberg , Johann Bauersachs Recommend Article Abstract Buy Article All articles of this category Die Peripartum-Kardiomyopathie ist eine vital bedrohliche Herzerkrankung, die bei zuvor herzgesunden Frauen gegen Ende der Schwangerschaft oder in den Folgemonaten nach Entbindung auftritt. Eine frühzeitige Diagnose und Therapie kann die Prognose der Patientinnen verbessern. Die interdisziplinäre Zusammenarbeit von Hebammen, Pränatal- und Geburtsmedizinern, Anästhesisten, Neonatologen, Allgemeinmedizinern sowie Kardiologen ist hierfür essenziell. Full Text References Literatur 1 GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1775-1812 2 Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J. et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39: 3165-3241 3 Nanna M, Stergiopoulos K. Pregnancy complicated by valvular heart disease: an update. J Am Heart Assoc 2014; 3: e000712 4 Hilfiker-Kleiner D, Haghikia A, Nonhoff J. et al. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 2015; 36: 1090-1097 5 Bauersachs J, Arrigo M, Hilfiker-Kleiner D. et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016; 18: 1096-1105 6 Sliwa K, Hilfiker-Kleiner D, Petrie MC. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12: 767-778 7 Sliwa K, Hilfiker-Kleiner D, Mebazaa A. et al. EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur J Heart Fail 2014; 16: 583-591 8 Bauersachs J, Koenig T. Devil in disguise: Hints and pitfalls in diagnosis of peripartum cardiomyopathy. Circ Heart Fail 2018; 11: e004620 9 Haghikia A, Podewski E, Libhaber E. et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013; 108: 366 doi:10.1007/s00395-013-0366-9 10 Sliwa K, Mebazaa A, Hilfiker-Kleiner D. et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail 2017; 19: 1131-1141 11 Irizarry OC, Levine LD, Lewey J. et al. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and Non-African American women. JAMA Cardiol 2017; 2: 1256-1260 12 Bauersachs J. Poor outcomes in poor patients? Peripartum cardiomyopathy – Not just black and white. JAMA Cardiol 2017; 2: 1261-1262 13 Hilfiker-Kleiner D, Kaminski K, Podewski E. et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128: 589-600 14 Halkein J, Tabruyn SP, Ricke-Hoch M. et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013; 123: 2143-2154 15 Patten IS, Rana S, Shahul S. et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485: 333-338 16 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129-2200 17 Haghikia A, Tongers J, Berliner D. et al. Early ivabradine treatment in patients with acute peripartum cardiomyopathy: subanalysis of the German PPCM registry. Int J Cardiol 2016; 216: 165-167 18 Hilfiker-Kleiner D, Haghikia A, Berliner D. et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017; 38: 2671-2679 19 Koenig T, Bauersachs J, Hilfiker-Kleiner D. Bromocriptine for the treatment of peripartum cardiomyopathy. Card Fail Rev 2018; 4: 46-49 20 Sliwa K, Blauwet L, Tibazarwa K. et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121: 1465-1473 21 McNamara DM, Elkayam U, Alharethi R. et al. Clinical outcomes for peripartum cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 2015; 66: 905-914 22 Hilfiker-Kleiner D, Haghikia A, Masuko D. et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail 2017; 19: 1723-1728 23 Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J 2017; 38: 2680-2682 24 Haghikia A, Schwab J, Vogel-Claussen J. et al. Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. Clin Res Cardiol 2018; 25 Duncker D, Haghikia A, Konig T. et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 2014; 16: 1331-1336 26 Duncker D, Westenfeld R, Konrad T. et al. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol 2017; 106: 582-589 27 Sieweke JT, Pfeffer TJ, Berliner D. et al. Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. Eur Heart J Acute Cardiovasc Care 2018; 28 Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 2011; 58: 659-670 29 Sliwa K, Petrie MC, Hilfiker-Kleiner D. et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail 2018; 30 Koenig T, Hilfiker-Kleiner D, Bauersachs J. Peripartum cardiomyopathy. Herz 2018; 43: 431-437 doi:10.1007/s00059-018-4709-z 31 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613-622
